Carocell Bio Presenting at BIO 2022

bio 2022, Mike Davies speaks about Carocell Bio

DURHAM, NORTH CAROLINA – 13 June 2022 – Carocell Bio, the anti-inflammation company revolutionising the treatment of inflammatory diseases with its peptide-based approach to mitogen-activated protein kinase inhibitors (MAPKi), has announced that its CEO, Mike Davies, who is attending the BIO 2022 International Convention, will be presenting today, Monday 13 June, at 12.30 pm PDT in Company Presentation Theater 3, San Diego Convention Center.

Over a period of four days, BIO 2022 aims to deliver inspiration and critical insights from global thought leaders, addressing critical topics at the intersection of science, business, and policy. Over 3,000 international and domestic companies have registered to attend the meeting, held in San Diego, USA, from across the international biotech industry.

Carocell Bio recently received approval from the UK’s Health Research Authority (HRA) to test lead candidate proprietary peptide JEL3108 in human burns and reconstructive surgery tissue samples. The company is focused on the topical application of its proprietary peptides, originally discovered at AstraZeneca, that target the body’s intracellular inflammation cascade via MAPKi, to inhibit MAPK which is a pivotal enzyme in pathways critical to the body’s inflammatory response. To-date, the company has received over USD $450,000 (GBP £370,000) in funding from Innovate UK to study the effect of the peptides in burns, in addition to USD $500,000 (approx. GBP £400,000) seed investment from Deepbridge Capital.

More articles